文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症中糖皮质激素的疗效、安全性及最佳方案:贝叶斯网络荟萃分析

The Efficacy, Safety, and Optimal Regimen of Corticosteroids in Sepsis: A Bayesian Network Meta-Analysis.
PubMed 文献 · Crit Care Explor · 2020-04-29
一句话结论贝叶斯网络荟萃分析提示,甲泼尼龙和地塞米松可能较安慰剂更有效降低脓毒症短期死亡率,氢化可的松200-400 mg/d、4-7天方案最可能获益。

本研究为贝叶斯网络荟萃分析,纳入35项随机对照试验、共8859例脓毒症患者,头对头比较不同糖皮质激素的疗效与安全性。结果显示,甲泼尼龙与地塞米松较安慰剂可能更有效降低短期死亡率(RR分别为0.65和0.42),氢化可的松及氢化可的松联合氟氢可的松较安慰剂缩短休克缓解时间及ICU住院时间,甲泼尼龙较安慰剂改善无通气天数。进一步分析提示,氢化可的松或等效剂量200-400 mg/d、疗程4-7天最可能获益。结论认为该剂量与疗程方案对脓毒症患者最可能有益,证据强度为中等。

要点

  • 甲泼尼龙较安慰剂可能降低脓毒症短期死亡率(RR 0.65,95%CI 0.40-0.93),地塞米松较安慰剂也可能降低(RR 0.42,95%CI 0.24-0.84)。
  • 氢化可的松较安慰剂缩短休克缓解时间(平均差-1.70天,95%CI -2.83至-0.92),氢化可的松联合氟氢可的松较安慰剂缩短2.54天(95%CI -4.19至-0.84)。
  • 氢化可的松较安慰剂缩短ICU住院时间(平均差-1.43天,95%CI -3.36至-0.15),甲泼尼龙较安慰剂改善无通气天数(平均差7.71天,95%CI 1.15-14.42)。
  • 氢化可的松或等效剂量200-400 mg/d较其他剂量降低死亡风险(RR 0.83,95%CI 0.64-0.98),疗程4-7天较其他疗程降低死亡风险(RR 0.78,95%CI 0.57-0.96)。
  • 作者认为,氢化可的松或等效剂量200-400 mg/d、疗程4-7天最可能使脓毒症患者获益,证据强度为中等。

适用人群与场景

  • 纳入35项随机对照试验中的8859例脓毒症患者,比较不同种类糖皮质激素与安慰剂或其他糖皮质激素的疗效与安全性。

处置流程与药物剂量

  • 甲泼尼龙较安慰剂可能更有效降低脓毒症短期死亡率(RR 0.65,95%CI 0.40-0.93)。
  • 地塞米松较安慰剂可能更有效降低脓毒症短期死亡率(RR 0.42,95%CI 0.24-0.84)。
  • 氢化可的松较安慰剂缩短休克缓解时间(平均差-1.70天,95%CI -2.83至-0.92),氢化可的松联合氟氢可的松较安慰剂缩短2.54天(95%CI -4.19至-0.84)。
  • 氢化可的松较安慰剂缩短ICU住院时间(平均差-1.43天,95%CI -3.36至-0.15)。
  • 甲泼尼龙较安慰剂改善无通气天数(平均差7.71天,95%CI 1.15-14.42)。
  • 氢化可的松或等效剂量200-400 mg/d较其他剂量降低死亡风险(RR 0.83,95%CI 0.64-0.98)。
  • 疗程4-7天较其他疗程降低死亡风险(RR 0.78,95%CI 0.57-0.96)。

研究设计与关键结果

  • 贝叶斯网络荟萃分析纳入35项随机对照试验、8859例脓毒症患者,检索PubMed、Embase和Cochrane Library至2019年12月28日。
  • 甲泼尼龙较安慰剂降低短期死亡率(RR 0.65,95%CI 0.40-0.93),地塞米松较安慰剂降低短期死亡率(RR 0.42,95%CI 0.24-0.84)。
  • 氢化可的松较安慰剂缩短休克缓解时间(平均差-1.70天,95%CI -2.83至-0.92),氢化可的松联合氟氢可的松较安慰剂缩短2.54天(95%CI -4.19至-0.84)。
  • 氢化可的松较安慰剂缩短ICU住院时间(平均差-1.43天,95%CI -3.36至-0.15),甲泼尼龙较安慰剂改善无通气天数(平均差7.71天,95%CI 1.15-14.42)。
  • 氢化可的松或等效剂量200-400 mg/d较其他剂量降低死亡风险(RR 0.83,95%CI 0.64-0.98),疗程4-7天较其他疗程降低死亡风险(RR 0.78,95%CI 0.57-0.96)。

证据类型、等级与局限

  • 证据类型:贝叶斯网络荟萃分析,纳入35项随机对照试验。
  • 证据强度:作者称本研究提供中等证据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,氢化可的松或等效剂量200-400 mg/d、疗程4-7天最可能使脓毒症患者获益,证据强度为中等。
  • 甲泼尼龙和地塞米松可能较安慰剂更有效降低脓毒症短期死亡率,氢化可的松及氢化可的松联合氟氢可的松可能缩短休克缓解时间,甲泼尼龙可能改善无通气天数。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Conventional systematic reviews have indicated that corticosteroids might result in a slight reduction in mortality in sepsis. However, the efficacy, safety, and optimal regimen of different corticosteroids partly remain unknown. In this study, we conducted a Bayesian network meta-analysis for a head-to-head comparison of the therapeutic efficacy and safety of currently used corticosteroids in sepsis.

DESIGN: A Bayesian network meta-analysis for a head-to-head comparison of the therapeutic efficacy and safety of currently used corticosteroids in sepsis.

SETTING: A total of 35 eligible randomized controlled trials of corticosteroid use in sepsis.

PATIENTS: The present Bayesian network meta-analysis included 8,859 patients with sepsis.

INTERVENTIONS: Randomized controlled trials were screened from PubMed, Embase, and the Cochrane Library up to December 28, 2019. A head-to-head comparison of the therapeutic efficacy and safety between the different categories of corticosteroids from the trials was conducted by Bayesian network meta-analysis. An empirical Bayesian meta-regression and a post hoc Bayesian network meta-analysis were performed to explore the appropriate dose and therapeutic duration of steroids for sepsis.

MEASUREMENTS AND MAIN RESULTS: A total of 35 randomized controlled trials including 8,859 patients with sepsis were enrolled in the final analysis. Bayesian network meta-analysis revealed that methylprednisolone and dexamethasone might be more effective in reducing short-term mortality in sepsis than placebo: methylprednisolone versus placebo (relative risk, 0.65, 95% credible interval 0.40-0.93), dexamethasone versus placebo (relative risk, 0.42, 95% credible interval, 0.24-0.84). Hydrocortisone and hydrocortisone plus fludrocortisone were superior to placebo in days to shock resolution (e-Table 5, Supplemental Digital Content 1, http://links.lww.com/CCX/A150): hydrocortisone versus placebo (mean difference, -1.70, 95% credible interval, -2.83 to -0.92), hydrocortisone plus fludrocortisone versus placebo (mean difference, -2.54, 95% credible interval, -4.19 to -0.84). Hydrocortisone was superior to placebo in reducing the length of stay in the ICU (mean difference, -1.43, 95% credible interval, -3.36 to -0.15). Methylprednisolone was superior to placebo in improving ventilation-free days (mean difference, 7.71, 95% credible interval, 1.15-14.42). In addition, further analysis indicated that the optimal therapeutic dosage was 200-400 mg per day of hydrocortisones or equivalents (relative risk, 0.83, 95% credible interval, 0.64-0.98), and the appropriate therapeutic duration was 4-7 days (relative risk, 0.78; 95% credible interval, 0.57-0.96).

CONCLUSIONS: This study provided moderate evidence that the dosage of 200-400 mg per day of hydrocortisone or equivalent for 4-7 days was most likely to benefit septic patients.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Zhang S, Chang W, Xie J, et al. The Efficacy, Safety, and Optimal Regimen of Corticosteroids in Sepsis: A Bayesian Network Meta-Analysis. Crit Care Explor. 2020. PMID: 32426736. doi:10.1097/CCE.0000000000000094

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。